Unigene Laboratories (OTC:UGNE) has release the third quarter earnings for 2009. The financial results report that revenue for the quarter ended September 30, was $2,732,000, down from the $5,084,000 earned during the same period the previous year. Fortical sales and royalties for the quarter were $2,398,000, compared to the previous year’s $4,277,000.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Stock Newsletter
Unigene Laboratories is engaged in the research, production and delivery of small proteins for medical use. The biopharmaceutical company manufactures technology to produce many of the small proteins known as peptides. The company also produces oral and nasal delivery technologies to deliver medically useful amounts of peptides into the bloodstream.
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Us
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
